drugset
drugset / Trial / NCT06992713

A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors

NCT06992713 ↗

Phase 1 Recruiting 36 enrolled Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.

Timeline

Start
2025-06-18
Primary completion
2026-09-04
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject H1710 Unknown — Other

Indications

neoplasm